<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945526</url>
  </required_header>
  <id_info>
    <org_study_id>Neuronutrition</org_study_id>
    <nct_id>NCT03945526</nct_id>
  </id_info>
  <brief_title>Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and NIHSS of Stroke Patients</brief_title>
  <official_title>Effect of Astaxanthin Supplementation on Plasma Malondialdehyde Levels and National Institute of Health Stroke Scale Score of Acute Ischemic Stroke Patients: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional randomized, controlled trial in analyzing the effects of
      astaxanthin supplementation on plasma malondialdehyde levels and NIHSS of acute ischemic
      stroke patients. According to published studies, it was hypothesized that acute ischemic
      stroke patients who were given astaxanthin would have lower plasma malondialdehyde levels and
      lower NIHSS score compared to the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There were a total of 24 subjects, with 12 subjects in the intervention group and 12 subjects
      in the control group.The participants were divided into an interventional group and a control
      group. The interventional group was given astaxanthin supplementation 2 x 8mg per day for 7
      days, while the control group was given placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2010</start_date>
  <completion_date type="Actual">June 9, 2010</completion_date>
  <primary_completion_date type="Actual">June 9, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Astaxanthin and Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Malondialdehyde Levels on Astaxanthine Treated Stroke Patients as Assessed by Wills Spectrophotometry</measure>
    <time_frame>7 days</time_frame>
    <description>This method used Thiobarbituric acid reaction (TBAR) with substances such as malondialdehyde. The scale was 0.367 nmol/ml-0.707 nmol/ml. The value above 0.707nmol/ml would be the worse outcome, and value less than 0.367nmol/ml would be the best outcome. Bivariate analysis was used to analyze the results (T-test or the Mann-Whitney Test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>National Institute of Health Stroke Scale on Astaxanthine Treated Stroke Patients</measure>
    <time_frame>7 days</time_frame>
    <description>Score scale was 4-15, where less than 4 indicates mild neurologic deficit, 4-15 moderate neurologic deficit, and more than 15 severe neurologic deficit. They will be assessed before and after the trial to compare how each participant improved after given the intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cerebral Stroke</condition>
  <condition>Malondialdehyde</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Astaxanthin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Astaxanthin supplementation will be given at 2 x 8mg for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo will be given, which takes the form of a drug with the exact same shape and color as astaxanthin supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Astaxanthine</intervention_name>
    <arm_group_label>Astaxanthin</arm_group_label>
    <other_name>Astaxanthine 8mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <other_name>Astaxanthine placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40-65 years old

          -  Has acute ischemic stroke with an onset of less than 48 hours before hospital
             admission

          -  NIHSS score of less than or equal to 15

          -  Can consume food orally or enterally

          -  Has given their consent to be a participant in the study

        Exclusion Criteria:

          -  Renal failure

          -  Liver failure

          -  Is taking supplements other than his or her main stroke medications

          -  Has taken antioxidant supplements in the last 3 months before stroke onset
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salim Harris, SpS</last_name>
    <role>Study Chair</role>
    <affiliation>IDI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sri Sukmaniah, SpGK</last_name>
    <role>Study Chair</role>
    <affiliation>IDI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nutrition University of Indonesia</name>
      <address>
        <city>Jakarta</city>
        <zip>10340</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Barber PA, Demchuk AM, Hirt L, Buchan AM. Biochemistry of ischemic stroke. Adv Neurol. 2003;92:151-64. Review.</citation>
    <PMID>12760178</PMID>
  </reference>
  <reference>
    <citation>Shen H, Kuo CC, Chou J, Delvolve A, Jackson SN, Post J, Woods AS, Hoffer BJ, Wang Y, Harvey BK. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009 Jun;23(6):1958-68. doi: 10.1096/fj.08-123281. Epub 2009 Feb 13.</citation>
    <PMID>19218497</PMID>
  </reference>
  <reference>
    <citation>Palozza P, Krinsky NI. Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch Biochem Biophys. 1992 Sep;297(2):291-5.</citation>
    <PMID>1497349</PMID>
  </reference>
  <reference>
    <citation>Hussein G, Nakamura M, Zhao Q, Iguchi T, Goto H, Sankawa U, Watanabe H. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull. 2005 Jan;28(1):47-52.</citation>
    <PMID>15635162</PMID>
  </reference>
  <reference>
    <citation>Gariballa SE, Sinclair AJ. Assessment and treatment of nutritional status in stroke patients. Postgrad Med J. 1998 Jul;74(873):395-9. Review.</citation>
    <PMID>9799909</PMID>
  </reference>
  <reference>
    <citation>Demirkaya S, Topcuoglu MA, Aydin A, Ulas UH, Isimer AI, Vural O. Malondialdehyde, glutathione peroxidase and superoxide dismutase in peripheral blood erythrocytes of patients with acute cerebral ischemia. Eur J Neurol. 2001 Jan;8(1):43-51.</citation>
    <PMID>11509080</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Gabriella Nurahmani Putri</investigator_full_name>
    <investigator_title>Assistant Clinical Nutrition Professor</investigator_title>
  </responsible_party>
  <keyword>Astaxanthin</keyword>
  <keyword>Antioxidant</keyword>
  <keyword>Plasma Malondialdehyde</keyword>
  <keyword>NIHSS score</keyword>
  <keyword>Ischemic Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

